Sue Washer | President and Chief Executive Officer |
Mark Shearman | Chief Scientific Officer |
William Sullivan | Chief Financial Office |
Joseph Pantginis | H.C. Wainwright & Co., LLC |
Matthew Luchini | BMO Capital Markets |
David Nierengarten | Wedbush Securities Inc. |
Zegbeh Jallah | ROTH Capital Partners |
Kristen Kluska | Cantor Fitzgerald |
Yanan Zhu | Wells Fargo Securities, LLC |
Good morning, and welcome to the AGTC Fourth Quarter and Fiscal Year 2020 Financial Results Conference Call. Today’s call is being recorded.
Before we get started, I’d like to remind everyone that during this conference call, AGTC may make forward-looking statements, including statements about the company’s financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its planned Phase 2/3 clinical trial. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic, and other risks described in Risk Factors section of AGTC’s most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. AGTC undertakes no obligations to update any forward-looking statements after the date of this call.